Evidence map›Paper›PMID 20385356›Full record

ArticleCancer cell2010

Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma.

Leigh A Compton, Scott W Hiebert

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2014
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Leigh A ComptonDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Scott W Hiebert
Vanderbilt University · US

Funding

Role of AML1-ETO in Acute LeukemiaR01CA064140 · NCI · VANDERBILT UNIVERSITY · PI HIEBERT, SCOTT W · 1994 to 2018
$5.7M
NCI NIH HHS R01 CA064140
6 · The paper itself

Abstract

Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.

Indexed as

DNA-Binding ProteinsHumansLymphoma, B-CellNuclear Receptor Co-Repressor 2Precision MedicineProto-Oncogene Proteins c-bcl-6BCL6 protein, humanDNA-Binding ProteinsNCOR2 protein, humanNuclear Receptor Co-Repressor 2Proto-Oncogene Proteins c-bcl-6

Identifiers

PMID20385356
OpenAlexW2050385509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.